中国药物警戒 ›› 2018, Vol. 15 ›› Issue (8): 506-512.
• 译文 • 上一篇
胡瑞学（译）1, 梁宁（译）1, 柴倩云（译）2, 杨国彦（译）3, 韩雪燕（译）4, 夏如玉（译）1, 严毓倩（译）1, 王迪（译）1, 文玲子（译）1, 黄娜（译）1, 杨国彦（校）3, 李迅（校）1, 刘建平（校）1, 费宇彤（校）1, *
收稿日期:2018-10-11
修回日期:2018-10-11
出版日期:2018-08-20
发布日期:2018-10-11
通讯作者:
费宇彤,女,博士,副研究员,临床研究方法学。E-mail:yutong_fei@163.com
作者简介:胡瑞学，男，硕士，循证中医药临床研究方法。
基金资助:
Received:2018-10-11
Revised:2018-10-11
Online:2018-08-20
Published:2018-10-11
中图分类号:
胡瑞学（译）, 梁宁（译）, 柴倩云（译）, 杨国彦（译）, 韩雪燕（译）, 夏如玉（译）, 严毓倩（译）, 王迪（译）, 文玲子（译）, 黄娜（译）, 杨国彦（校）, 李迅（校）, 刘建平（校）, 费宇彤（校）. PRISMA危害报告清单：改进系统综述中危害的报告（三）[J]. 中国药物警戒, 2018, 15(8): 506-512.
| [1] Moher David,Liberati Alessandro,Tetzlaff Jennifer, et al.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement[J] .PLoS Med., 2009, 6(7): e1000097. [2] Gray JAM.Evidence-based healthcare.How to make health policy and management decisions[M] .Churchill Livingstone, 2001. [3] Sackett D L,Wennberg J E.Choosing the best research design for each question[J]. BMJ, 1997, 315(7123): 1636. [4] Ioannidis John P A. Adverse events in randomized trials: neglected, restricted, distorted, and silenced[J] .Arch. Intern. Med., 2009, 169(19): 1737-1739. [5] Singh Sonal,Loke Yoon K.Drug safety assessment in clinical trials: methodological challenges and opportunities[J].Trials, 2012, 13(1): 138. [6] Papanikolaou Panagiotis N,Ioannidis John P A. Availability of large-scale evidence on specific harms from systematic reviews of randomized trials[J]. Am. J. Med., 2004, 117(8): 582-589. [7] Pitrou Isabelle,Boutron Isabelle,Ahmad Nizar, et al.Reporting of safety results in published reports of randomized controlled trials[J]. Arch. Intern. Med., 2009, 169(19): 1756-1761. [8] Loke Y K,Derry S.Reporting of adverse drug reactions in randomised controlled trials-a systematic survey[J]. BMC Clin Pharm- acol, 2001, 1(1): 3. [9] Ioannidis J P,Lau J.Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas[J]. JAMA, 2001, 285(4): 437-443. [10] Yazici Yusuf.Some concerns about adverse event reporting in randomized clinical trials[J]. Bull NYU Hosp Jt Dis, 2008, 66(2): 143-145. [11] Ernst E,Pittler M H.Assessment of therapeutic safety in systematic reviews: literature review[J]. BMJ, 2001, 323(7312): 546. [12] Zorzela Liliane,Golder Su,Liu Yali, et al.Quality of reporting in systematic reviews of adverse events: systematic review[J]. BMJ, 2014, 348: f7668. [13] Golder Su,Loke Yoon K,Zorzela Liliane.Some improvements are apparent in identifying adverse effects in systematic reviews from 1994 to 2011[J]. J Clin Epidemiol, 2013, 66(3): 253-260. [14] McIntosh Heather M,Woolacott Nerys F,Bagnall Anne-Marie. Assessing harmful effects in systematic reviews[J]. BMC Med Res Methodol, 2004, 4(1): 19. [15] Cornelius V R,Perrio M J,Shakir S A W, et al. Systematic reviews of adverse effects of drug interventions: a survey of their conduct and reporting quality[J]. Pharmacoepidemiol Drug Saf, 2009, 18(12): 1223-1231. [16] Loke Yoon K,Golder Su P,Vandenbroucke Jan P.Comprehensive evaluations of the adverse effects of drugs: importance of appropriate study selection and data sources[J]. Ther Adv Drug Saf, 2011, 2(2): 59-68. [17] Chou Roger, Fu Rongwei,Carson Susan, et al.Methodological shortcomings predicted lower harm estimates in one of two sets of studies of clinical interventions[J]. J Clin Epidemiol, 2007, 60(1): 18-28. [18] Chou Roger,Helfand Mark.Challenges in systematic reviews that assess treatment harms[J]. Ann. Intern. Med., 2005, 142(2): 1090-1099. [19] Hopewell Sally,Wolfenden Luke,Clarke Mike.Reporting of adverse events in systematic reviews can be improved: survey results[J]. J Clin Epidemiol, 2008, 61(6): 597-602. [20] Hernandez Adrian V,Walker Esteban,Ioannidis John P A et al. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone[J]. Am. Heart J., 2008, 156(1): 23-30. [21] Stroup D F,Berlin J A,Morton S C, et al.Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta- analysis Of Observational Studies in Epidemiology (MOOSE) group[J]. JAMA, 2000, 283(15): 2008-2012. [22] Moher David,Schulz Kenneth F,Simera Iveta, et al.Guidance for developers of health research reporting guidelines[J]. PLoS Med., 2010, 7(2): e1000217. [23] Beller Elaine M,Glasziou Paul P,Altman Douglas G, et al.PRISMA for Abstracts: reporting systematic reviews in journal and conference abstracts[J]. PLoS Med., 2013, 10(4): e1001419. [24] Shamseer Larissa,Moher David,Clarke Mike, et al.Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation[J]. BMJ, 2015, 350(1): g7647. [25] Pilkington Karen,Boshnakova Anelia.Complementary medicine and safety: a systematic investigation of design and reporting of systematic reviews[J]. Complement Ther Med, 2012, 20(1-2): 73-82. [26] Murphy M K,Black N A,Lamping D L, et al. Consensus development methods,their use in clinical guideline development[J].Health Technol Assess, 1998, 2(3): i-iv, 1-88. [27] Higgins J P T, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Cochrane Collaboration, 2011. www.cochrane-handbook.org. [28] Chou Roger,Aronson Naomi,Atkins David, et al.AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program[J].J Clin Epidemiol, 2010, 63(5): 502-512. [29] Ioannidis John P A,Evans Stephen J W,G tzsche Peter C, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement[J]. Ann. Intern. Med., 2004, 141(10): 781-788. [30] Loke Yoon K,Price Deirdre,Herxheimer Andrew, et al.Systematic reviews of adverse effects: framework for a structured approach[J].BMC Med Res Methodol, 2007, 7(1): 32. [31] Arbyn M,Kyrgiou M,Simoens C, et al.Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis[J]. BMJ, 2008, 337(7673): a1284. [32] Loke Yoon Kong,Jeevanantham Vinodh,Singh Sonal.Bisphosphonates and atrial fibrillation: systematic review and meta-analysis[J]. Drug Saf, 2009, 32(3): 219-228. [34] Banach Ryan,Boskovic Radinka,Einarson Thomas, et al.Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta- analysis of cohort studies[J]. Drug Saf, 2010, 33(1): 73-79. [35] Loke Yoon Kong,Kwok Chun Shing,Singh Sonal.Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies[J]. BMJ, 2011, 342(7799): d1309. [36] Agbabiaka Taofikat B,Pittler Max H,Wider Barbara, et al.Serenoa repens (saw palmetto): a systematic review of adverse events[J].Drug Saf, 2009, 32(8): 637-647. [37] Hammad Tarek A,Neyarapally George A,Pinheiro Simone P, et al.Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: an empirical assessment[J].Clin Trials, 2013, 10(3): 389-397. [38] Michele Theresa M,Pinheiro Simone,Iyasu Solomon.The safety of tiotropium-the FDA's conclusions[J]. N. Engl. J. Med., 2010, 363(12): 1097-1099. [39] Anello C, O'Neill R T. Does research synthesis have a place in drug regulatory policy?[J].Clin Res Regul A., 1996,13:13-21. [40] Golder Su,Loke Yoon,McIntosh Heather M. Room for improvement? A survey of the methods used in systematic reviews of adverse effects[J]. BMC Med Res Methodol, 2006, 6(1): 3. [41] Golder Su,Loke Yoon K,Bland Martin.Unpublished data can be of value in systematic reviews of adverse effects: methodological overview[J]. J Clin Epidemiol, 2010, 63(10): 1071-1081. [42] Bangalore Sripal,Kumar Sunil,Wetterslev J rn, et al. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials[J]. BMJ, 2011, 342(7805): d2234. [43] Golder Su,Loke Yoon,McIntosh Heather M. Poor reporting and inadequate searches were apparent in systematic reviews of adverse effects[J]. J Clin Epidemiol, 2008, 61(5): 440-448. [44] Derry S,Loke Y K,Aronson J K.Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials[J]. BMC Med Res Methodol, 2001, 1(1): 7. [45] Golder Su,Loke Yoon K.The contribution of different information sources for adverse effects data[J]. Int J Technol Assess Health Care, 2012, 28(2): 133-137. [46] Golder Su,Loke Yoon Kong.Failure or success of electronic search strategies to identify adverse effects data[J]. J Med Libr Assoc, 2012, 100(2): 130-134. [47] Bellis J R,Pirmohamed M,Nunn A J, et al.Dexamethasone and haemorrhage risk in paediatric tonsillectomy: a systematic review and meta-analysis[J]. Br J Anaesth, 2014, 113(1): 23-42. [48] Leombruno J P,Einarson T R,Keystone E C.The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events[J]. Ann. Rheum. Dis., 2009, 68(7): 1136-1145. [49] Albavera-Hernández Cidronio,Rodríguez Jorge M,Idrovo Alvaro J.Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials[J]. Clin Rehabil, 2009, 23(5): 394-407. [50] Rücker Gerta,Schwarzer Guido,Carpenter James, et al.Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells[J]. Stat Med, 2009, 28(5): 721-738. [51] Bradburn Michael J,Deeks Jonathan J, Berlin Jesse A, et al.Much ado about nothing: a comparison of the performance of meta- analytical methods with rare events[J]. Stat Med, 2007, 26(1): 53-77. [52] Sweeting Michael J,Sutton Alexander J,Lambert Paul C.What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data[J]. Stat Med, 2004, 23(9): 1351-1375. [53] Stijnen Theo,Hamza Taye H,Ozdemir Pinar.Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data[J]. Stat Med, 2010, 29(29): 3046-3067. [54] Mattishent K,Loke Y K.Bi-directional interaction between hypoglycaemia and cognitive impairment in elderly patients treated with glucose-lowering agents: a systematic review and meta- analysis[J]. Diabetes Obes Metab, 2016, 18(2): 135-141. [55] Saini Pooja,Loke Yoon K,Gamble Carrol, et al.Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews[J]. BMJ, 2014, 349(nov21): g6501. [56] Loke Yoon Kong,Mattishent Katharina.If nothing happens, is everything all right? Distinguishing genuine reassurance from a false sense of securit[J]. CMAJ, 2015, 187(1): 15-16. [57] Kirkham Jamie J,Dwan Kerry M,Altman Douglas G, et al.The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews[J].BMJ, 2010, 340(7741): c365. [58] Page Matthew J,McKenzie Joanne E,Kirkham Jamie, et al. Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions[J].Cochrane Database Syst Rev, 2014. [59] Keus F,Wetterslev J,Gluud C, et al.Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials[J]. Am. J. Gastroenterol., 2009, 104(3): 546-551. [60] Chan An-Wen,Hróbjartsson A,Haahr Mette T, et al.Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles[J]. JAMA, 2004, 291(20): 2457-2465. [61] Scharf Orit,Colevas A Dimitrios.Adverse event reporting in publications compared with sponsor database for cancer clinical trials[J]. J. Clin. Oncol., 2006, 24(24): 3933-3938. [62] Mahoney Michelle R,Sargent Daniel J.Adverse-event rates: journals versus databases[J]. Lancet, 2007, 369(9557): 171-172. [63] Chan An-Wen,Krleza-Jeri Karmela,Schmid Isabelle, et al.Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research[J]. CMAJ, 2004, 171(7): 735-740. [64] Sterne Jonathan A C,Sutton Alex J,Ioannidis John P A, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials[J]. BMJ, 2011, 343(5): d4002. [65] Lau Joseph,Ioannidis John P A,Terrin Norma, et al. The case of the misleading funnel plot[J]. BMJ, 2006, 333(7568): 597-600. [66] Lathyris Dimitrios,Panagiotou Orestis A,Baltogianni Maria, et al.Safety of medical interventions in children versus adults[J]. Pediatrics, 2014, 133(3): e666-673. [67] Singh Sonal,Loke Yoon K,Enright Paul L, et al.Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials[J].BMJ, 2011, 342(7811): d3215. [68] Ioannidis John P A,Patsopoulos Nikolaos A,Rothstein Hannah R. Reasons or excuses for avoiding meta-analysis in forest plots[J].BMJ, 2008, 336(7658): 1413-1415. [69] Bain E S, Middleton P F, Crowther C A.Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review[J]. BMC Pregnancy Childbirth,2013,13:195. [70] Langendam Miranda W,Tiemersma Edine W,van der Werf Marieke J, et al. Adverse events in healthy individuals and MDR-TB contacts treated with anti-tuberculosis drugs potentially effective for preventing development of MDR-TB: a systematic review[J]. PLoS ONE, 2013, 8(1): e53599. [71] Jolivot Pierre-Alain,Hindlet Patrick,Pichereau Claire, et al.A systematic review of adult admissions to ICUs related to adverse drug events[J].Crit Care, 2014, 18(6): 643. [72] K tter Thomas,da Costa Bruno R,F ssler Margrit, et al. Metamizole- associated adverse events: a systematic review and meta-analysis[J]. PLoS One, 2015, 10(4): e0122918. [73] Meyer-Massetti Carla,Cheng Christine M,Sharpe Bradley A, et al.The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?[J].J Hosp Med, 2010, 5(4): E8-16. [74] HILL A B.The Environment And Disease: Association Or Causation?[J] .Proc. R. Soc. Med., 1965, 58: 295-300. [75] Uppsala Monitoring Centre. World Health Organization causality assessment criteria.2015. who-umc.org. [76] Shuster Jonathan J,Jones Lynn S,Salmon Daniel A.Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death[J].Stat Med, 2007, 26(24): 4375-4385. [77] Shuster Jonathan J.Empirical vs natural weighting in random effects meta-analysis[J]. Stat Med, 2010, 29(12): 1259-1265. [78] Ioannidis John P A,Hozo Iztok,Djulbegovic Benjamin. Optimal type I and type II error pairs when the available sample size is fixed[J]. J Clin Epidemiol, 2013, 66(8): 903-910. [79] Fernández-Balsells M Mercè,Murad Mohammad Hassan,Lane Melanie, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis[J]. J. Clin. Endocrinol. Metab., 2010, 95(6): 2560-2575. [80] Hohl Corinne M,Kelly-Smith Carolyn H,Yeung Titus C, et al. The effect of a bolus dose of etomidate on cortisol levels, mortality, and health services utilization: a systematic review[J]. Ann Emerg Med, 2010, 56(2): 105-113. [81] Moher David,Glasziou Paul,Chalmers Iain, et al.Increasing value and reducing waste in biomedical research: who's listening?[J] .Lancet, 2016, 387(10027): 1573-1586. [82] Glasziou Paul,Altman Douglas G,Bossuyt Patrick, et al.Reducing waste from incomplete or unusable reports of biomedical research[J]. Lancet, 2014, 383(9913): 267-276. [83] Shamseer Larissa,Galipeau James,Turner Lucy, et al.Improving the reporting and usability of research studies[J]. Can J Anaesth, 2013, 60(4): 337-339. [84] Turner Lucy,Shamseer Larissa,Altman Douglas G, et al.Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review[J].Syst Rev, 2012, 1(1): 60. [85] Macleod Malcolm R,Michie Susan,Roberts Ian, et al.Biomedical research: increasing value, reducing waste[J]. Lancet, 2014, 383(9912): 101-104. |
| [1] | 贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166. |
| [2] | 马美英, 赵晓佩, 张梦瑶, 胡一琳. 我国药品追溯码编码制度研究探讨[J]. 中国药物警戒, 2024, 21(2): 167-172. |
| [3] | 朱盈, 沈璐, 李岚, 吴建民, 高晓洁. 新法规体系下我国牙膏不良反应监测工作分析与思考[J]. 中国药物警戒, 2024, 21(2): 219-222. |
| [4] | 高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5. |
| [5] | 马丽娜, 胡晓祯, 郑长辉, 孙颖, 赵旭, 曹俊岭, 肖小河. 基于“因毒为能”思想的有毒中药常山毒效转化知识图谱可视化分析[J]. 中国药物警戒, 2024, 21(1): 25-32. |
| [6] | 刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101. |
| [7] | 田春华, 吴桂芝. 定期获益-风险评估报告在我国的实施思考[J]. 中国药物警戒, 2023, 20(12): 1382-1384. |
| [8] | 赵燕, 李尧, 宋雅娜, 郑立佳, 李栋, 赵一飞, 卞蓉蓉, 董放. 警戒视域下开展医疗器械上市后主动监测的实践研究与思考[J]. 中国药物警戒, 2023, 20(12): 1385-1390. |
| [9] | 逄瑜, 刘博, 吴文宇, 田月洁, 王涛. 英国患者报告制度建立的浅析与启示[J]. 中国药物警戒, 2023, 20(11): 1259-1263. |
| [10] | 吴昀效, 于玥琳, 王胜锋, 孙凤, 孟若谷, 詹思延. 真实世界数据在疫苗上市后安全性主动监测中适用性评价分析[J]. 中国药物警戒, 2023, 20(10): 1081-1089. |
| [11] | 贾晋生, 王青, 刘红亮, 侯永芳. 药品上市许可持有人药物警戒工作评估指标体系的探索[J]. 中国药物警戒, 2023, 20(10): 1090-1094. |
| [12] | 刘红亮, 王青, 侯永芳. 基于真实世界数据老年常见病多重用药风险数据管理平台设计与实施[J]. 中国药物警戒, 2023, 20(10): 1095-1098. |
| [13] | 夏旭东, 黎美霞, 孙阳, 杨胜亚. 药品上市许可持有人药物警戒远程检查流程探讨[J]. 中国药物警戒, 2023, 20(9): 967-970. |
| [14] | 里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977. |
| [15] | 沈艳杰, 吴奕卿. 临床试验期间不良事件管理的实践与思考[J]. 中国药物警戒, 2023, 20(9): 982-986. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
